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doi:10.1016/j.jfma.2011.05.012Both severe thyrotoxicosis and hypothyroidism may affect brain function and cause a change in
consciousness, as seen with a thyroid storm or myxedema coma. However, encephalopathy
may also develop in patients with autoimmune thyroid diseases independent of actual thyroid
function level, and this is known as Hashimoto’s encephalopathy. Although most patients are
found to have Hashimoto’s thyroiditis, less frequently they have Graves’ disease. Clinical
manifestations include epilepsy, disturbance of consciousness, cognitive impairment, memory
loss, myoclonus, hallucinations, stroke-like episodes, tremor, involuntary movements,
language impairment, and gait impairment. Hashimoto’s encephalopathy is a relatively rare
disease. As a good response can be obtained with corticosteroid therapy, early diagnosis and
treatment is very beneficial for patients. Here we report three patients with Hashimoto’s
encephalopathy with typical manifestations of hallucinations that were associated with hypo-
thyroidism, hyperthyroidism, and euthyroid status, respectively. They all showed a dramatic
response to methylprednisolone pulse therapy.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.1
Introduction
Both severe thyrotoxicosis and hypothyroidism may affect
brain function. Some encephalopathies that develop in
patients with autoimmune thyroiditis are, however, inde-
pendent of actual thyroid function level, and these are
known as Hashimoto’s encephalopathy. The first case wasof Internal Medicine, National
n South Road, Taipei, Taiwan.
u.edu.tw (T.-C. Chang).
ight ª 2012, Elsevier Taiwan LLCreported by Brain et al. in 1966, and so far only about 200
cases have been reported, in adults as well as children.2
Schizophrenia is associated with genetic and environ-
mental factors, and changes in neurotransmitter levels.
The clinical picture consists of delusions, hallucinations,
disorganized thinking, loss of social skills, stiffness, and
other neuropsychiatric symptoms. However, some physical
illnesses, such as electrolyte imbalance, hypoglycemia,
central nervous system infections, thyroid and parathyroid
diseases, liver and kidney failure, systemic lupus eryth-
ematosus, seizures, and neoplasms may induce similar
psychotic symptoms.3& Formosan Medical Association. All rights reserved.
Hashimoto’s encephalopathy: Report of three cases 863Therefore, for all patients with unexplained acute or
subacute encephalopathy, or atypical psychiatric manifes-
tations, especially patients who have autoimmune thyroid
disease, Hashimoto’s encephalopathy must be included in
the differential diagnosis. Here we present three cases of
Hashimoto’s encephalopathy associated with hypothy-
roidism, hyperthyroidism, and euthyroid status, respectively.
Case reports
Case 1
This patient was a 46-year-old man, who was relatively
well, with no long-term medications or substance abuse
history. He worked as a community security guard, and was
responsible and friendly to the community residents and his
co-workers. About 6 months before admission, he had pre-
sented with depressed mood, bilateral lower leg weakness,
and inability to concentrate. Furthermore, his younger
brother noticed self-talking behavior, paranoid ideas, and
intermittent crying. Therefore, the man was brought to our
hospital for admission.
On admission, physical evaluation disclosed clear
consciousness but slow responses, a low-pitched voice,
coarse hair, a moderately diffuse goiter, low body temper-
ature (35.4C), hand tremor, and myoclonus. Vivid visual
hallucinations, auditory hallucinations, and paranoid ideas
were also noted. Laboratory evaluation showed a free
thyroxine (T4) level <3.48 pmol/L, high-sensitivity thyroid
stimulating hormone hsTSH) of 159.7 mIU/L, an antithyroid
peroxidase (anti-TPO) antibody value of 1697.78 IU/mL,
antithyroglobulin antibody (ATA) level of 154.07 IU/mL,
creatine kinase of 14.4 mkat/L, and total cholesterol of
4.69 mmol/L (Table 1).
Thyroid echography showed a diffuse isoechoic and
heterogeneous picture, which was compatible with auto-
immune thyroiditis. Levothyroxine was prescribed for
Hashimoto’s thyroiditis with hypothyroidism. Magnetic
resonance imaging (MRI) of the brain disclosed only mild
prominent and symmetrical sulci, fissures, and ventricles.
Electroencephalography (EEG) showed mild diffuse cortical
dysfunction. The cerebrospinal fluid (CSF) had a slightly
increased protein concentration (0.78 g/L), increased
immunoglobulin G (IgG) level (0.18 g/L), a raised albuminTable 1 Serum levels of free thyroid hormones, thyrotropin, an
Hashimoto’s encephalopathy described in the text.
Case 1 Case 2
Hormones
fT4 (pmol/L) <3.48 25.87
hsTSH (mIU/L) 159.7 <0.004
Autoantibodies
Anti-TPO (IU/mL) 1697.78
AMA 1:20480
ATA (IU/mL) 154.07 1:20480
ATAZ anti-thyroglobulin antibodies; AMAZ antimicrosomal antibody
bodies; fT4Z free thyroxine; hsTSHZ high sensitive thyroid-stimulat
titer; e means negative and normal.concentration with a higher CSF:serum IgG ratio (0.007) and
albumin ratio (0.01162), but no pleocytosis. In addition,
positive ATA (2.03 IU/mL) and anti-TPO antibody (11.55 IU/
ml) were also noted (Table 2).
Intravenous infusion therapy with methylprednisolone
500 mg in 200 mL normal saline for 30 minutes on three
consecutive days rapidly improved the clinical picture. The
visual hallucinations, auditory hallucinations, and paranoid
ideas also totally recovered. Loss of short-term memory was
noted. A subsequent EEG study 2 weeks later was normal.
The patient has now been symptom-free for 8 months
without any recurrences, and has been followed up in the
outpatient department to monitor his levothyroxine supple-
mental therapy. He has been able to work and maintain
independent daily living during the follow-up period.Case 2
The second patient was a 56-year-old woman known to be
affected by Graves’ disease with Graves’ orbitopathy
diagnosed when she was 43 years old by a moderate diffuse
goiter and initial laboratory data revealing free T4 of
28.32 pmol/L, hsTSH of 0.06 mIU/L, antimicrosomal anti-
body 1:20480 (þ), and ATA 1:20480 (þ). Thyroid echography
showed a homogeneous diffusely isoechoic picture, which
was compatible with Graves’ disease. After taking methyl-
prednisolone pulse therapy for active Graves’ orbitopathy,
the patient was treated with antithyroid drugs. Antithyroid
drugs were discontinued after a total of 9 years’ treatment
when she was in a euthyroid state.
About 2 months after discontinuing her antithyroid drugs,
thepatient presentedwith disturbanceof consciousness, gait
disturbance, bilateral tremor of the hands, and delirium.
Physical evaluation disclosed a body temperature of 36.2C
and sinus tachycardia (heart rate 110 beats per minute).
Laboratory data showed a free T4 value of 45.05 pmol/L and
hsTSH <0.004 mIU/L. Brain MRI revealed non-specific find-
ings, and EEG recording showed moderate diffuse cortical
dysfunction. Suspecting a thyroid storm, high-dose pro-
pylthiouracil, beta-blockers, diluted Lugol’s solution, and
corticosteroid were prescribed, with a favorable response.
However, disturbance of consciousness, unstable gait,
and visual hallucinations occurred 1 month later when the
dose of steroid was tapered off. Physical examinationd thyroid autoantibodies observed in the three patients with
Case 3 Reference range
13.51 7.72e22.52
0.64 0.1e4.0
<5.61
(þ) 1:1280(þ) <1:80 (e)
(þ) 1:5120(þ) <14.4
<1:80 (e)
, presented as titers; anti-TPOZ anti-thyroid peroxidase anti-
ing hormone; þ means positive finding, and elevation of antibody
Table 2 Cerebrospinal fluid (CSF) data in a 46-year-old
man affected by Hashimoto’s encephalopathy (Case 1).
Parameters Values Reference
values
Appearance Clear,
colourless
e
Glucose (mmol/L) 3.16 2.78e4.16
Proteins (g/L) 0.78 <0.5
Albumin (g/L) 0.49 0.1e0.35
IgG (g/L) 0.18 <0.04
Oligoclonal IgG band Absent Absent
CSF:serum IgG ratio 0.007 <0.003
CSF:serum albumin ratio 0.01162 <0.009
Anti-TPO antibody (IU/mL) 11.55 Negative
ATA (IU/mL) 2.03 Negative
Erythrocytes 0 Absent
Leucocytes (n/mm3) 0 <5
Lymphocytes (n/%) 0 40e80
Stain for microorganisms,
including acid-fast bacteria,
and antibodies for
infectious pathogens
Negative Negative
ATAZ anti-thyroglobulin antibodies; anti-TPOZ anti-thyroid
peroxidase antibodies; IgGZ immunoglobulin G.
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no fever (body temperature 36.8 C). Laboratory evaluation
disclosed free T4 25.87 pmol/L and hsTSH <0.004 mIU/L
(see Table 1). A diagnosis of Hashimoto’s encephalopathy
was suspected as the changes in thyroid hormone status
could not justify the patient’s symptoms.
She was treated with intravenous methylprednisolone
500 mg daily for 3 days, which resulted in a dramatic
improvement. Loss of recent memory, especially relating
to before admission, was also noted. Oral prednisone was
prescribed and slowly tapered off within 9 months. The
patient did not show any neuropsychiatric alterations even
after corticosteroids had been discontinued. She was
symptom-free for 5 years and was maintained in euthyroid
state with low-dose propylthiouracil treatment for Graves’
disease.
Case 3
A 76-year-old woman suffering from Hashimoto’s thyroiditis
was under regular medical control for hypertension. She
had developed psychotic symptoms in the form of auditory
hallucinations and persecutory delusions when she was 70
years old, and was then treated with low-dose risperidone
treatment.
After about 3 years of stable treatment, there was a flare-
up of her psychotic symptoms with disturbing behavior. Her
consciousness was clear, but she suffered severe persecutory
delusions and auditory hallucinations, and a moderate
diffuse goiter was noted. Laboratory evaluation showed free
T4 13.51 pmol/L, hsTSH 0.64 mIU/L, antimicrosomal anti-
body 1:1280 (þ), and ATA 1:5120 (þ) (see Table 1). An EEG
showed intermittent slow waves in both temporal areas, and
MRI of the brain revealed nonspecific findings.As this prompted a suspicion of Hashimoto’s encepha-
lopathy, methylprednisolone 500 mg intravenous pulse
therapy was given for 3 days, with a rapid improvement in
the patient’s delusions. She received repeated steroid
pulse therapies 1 and 6 months after first dose of methyl-
prednisolone pulse therapy due to a flare-up of her
psychotic symptoms, with a favorable response in both
instances. Follow-up laboratory data showed decreased
antimicrosomal antibody (1:1280 þ) and ATA (1:640 þ)
titers, and the EEG was normal. The patient was regularly
followed up in the outpatient department for 3 years, her
psychotic symptoms remaining stable with low-dose anti-
psychotic agents.Discussion
Hashimoto’s encephalopathy is a rare disease, with a prev-
alence of 2.1/100,000.4 As with other autoimmune thyroid
diseases, Hashimoto’s encephalopathy occurs predomi-
nantly in females, with a male to female ratio of approxi-
mately 1:5, and the mean age of onset is between 45 and
55 years.5 Most patients with Hashimoto’s encephalopathy
are affected by Hashimoto’s thyroiditis, although a small
number have Graves’ disease. The clinical features do not
differ between patients with Hashimoto’s thyroiditis or
Graves’ disease.6
The pathogenesis of Hashimoto’s encephalopathy is still
unknown. There is no evidence that the anti-TPO antibody
directly causes encephalopathy, but other autoantibodies
that associated with autoimmune thyroid diseases might
induce encephalopathy. Some autopsy reports have noted
that Hashimoto’s encephalopathy may be associated with
lymphocytic infiltration and vasculitis in the brainstem or
brain graymatter.7 Severalmechanisms, such as autoimmune
vasculitis, autoantibodies against brain-thyroid antigens,
encephalomyelitis-associated demyelination, global cerebral
hypoperfusion, a direct toxic effect of thyrotropin-releasing
hormone, and neuronal dysfunction due to brain edema
have been proposed for Hashimoto’s encephalopathy.8
The condition is known by many names that refer to
different pathophysiological mechanisms: (1) steroid-
responsive encephalopathy associated with thyroid auto-
immunity: with an emphasis on a good response to steroid
therapy; (2) non-vasculitic autoimmune inflammatory
meningoencephalitis, which covers many different etiolo-
gies; (3) Hashimoto’s encephalopathy, as most patients
have underlying Hashimoto’s thyroiditis; and (4) encepha-
lopathy associated with autoimmune thyroid disease, which
contains a broad spectrum of conditions, not only Hashi-
moto’s thyroiditis, but also Graves’ disease.9
Hashimoto’s encephalopathy is characterized by numerous
neurological and neuropsychiatric symptoms. The clinical
manifestations include epilepsy and disturbance of
consciousness (51%), cognitive impairment and memory
loss (48%), myoclonus (32%), hallucinations and psychotic
symptoms (26%), stroke-like symptoms (21%), tremor and
involuntary movements (12%), language barrier (8%), and
ataxia (6%).10 In children, the prevalence is still higher in
girls than boys. The most common symptoms are seizures,
altered consciousness, headache, and hallucinations.
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encephalopathy may manifest as subclinical hypothyroidism
(35%), euthyroidism (30%), overt hypothyroidism (20%), or,
less frequently, hyperthyroidism (7%).11 It is different from
myxedema coma or thyroid storm because the change in
consciousness that occurs in Hashimoto’s encephalopathy is
unrelated to the level of thyroid hormone. As in our Case 2,
although the thyroid hormone level was elevated, patient
kept afebrile while consciousness disturbance developed.
Because thyroid storm could not be completely ruled out in
that case, the patient was initially treated for this.
Psychotic symptoms recurred while the steroid dosage was
being tapered off, and the changes in thyroid hormone were
unable to justify the symptoms. Thus, a diagnosis of
Hashimoto’s encephalopathy was a high probability. After
steroid pulse therapy with a good response, the diagnosis
was confirmed.
According to the literature, psychosis may develop
under steroid therapy, and the symptoms will improve after
tapering the steroid off.12 Steroid withdrawal syndrome is
much more likely to be associated with symptoms of fever,
anorexia, nausea, lethargy, and arthralgias, which resem-
bles those of adrenal insufficiency.13 In the second case we
described here, the symptoms do not match the above
criteria.
After excluding other possible etiologies of encepha-
lopathy, Hashimoto’s encephalopathy must be suspected in
all patients with autoimmune thyroid disease who develop
unexplained acute or subacute encephalopathy. The diag-
nostic criteria for Hashimoto’s encephalopathy include: (1)
a lack of other diseases such as infection, stroke, metabolic
diseases, and other factors accounting for the acute or
subacute encephalopathy; (2) euthyroidism or thyroid
hormone changes that are unable to justify the symptoms;
(3) an association with autoimmune thyroid diseases with
an elevated plasma anti-TPO antibody level; and (4)
a favorable response to corticosteroid therapy. If the
patient’s condition meets the above criteria, Hashimoto’s
encephalopathy can be diagnosed.14
As in our first case, additional clues may be provided
by the detection of anti-TPO antibody and ATA, and an
increase in protein concentration or IgG level in the CSF
without pleocytosis.15 Computed tomography scans, MRI of
the brain and EEG traces are either normal or present with
nonspecific findings. The role of imaging studies is mainly to
exclude other possible causes of encephalopathy.
The literature reports that alpha-enolase and a 36-kDa
protein, detected in a soluble fraction from the cerebral
cortex, may play a role in Hashimoto’s encephalopathy.16,17
A further study suggests that autoantibodies are directed
against the amino-terminal portion of alpha-enolase.18
Thus, the detection of anti-alpha-enolase antibodies could
be a possible additional tool in diagnosis. Elevated CSF
protein levels during exacerbations that normalize during
remission are reported.11 The EEG also showed normaliza-
tion after treatment; however, this occurs approximately 2
weeks later than the clinical improvement.19
Treatment for Hashimoto’s encephalopathy is divided
into three categories. The first approach is to use immu-
nomodulatory agents. When Hashimoto’s encephalopathy is
suspected, corticosteroid treatment is advised as the first-
line therapeutic choice. Various regimens of corticosteroidtreatment have been proposed. According to the literature,
methylprednisolone 1000 mg as an intravenous infusion for
3e5 days is recommended.20 In Chinese patients, as shown
by our experience in the three cases described above, the
recommended dose can be reduced to methylprednisolone
500 mg intravenous infusion for 3 days to decrease the
incidence of iatrogenic Cushing’s syndrome and the risk for
osteoporosis. The neurological symptoms usually respond
within 1 week, sometimes as quickly as 1 day. In up to 40%
of patients, there is no recurrence after the first course of
corticosteroid pulse therapy.9
Occasional steroid resistance and a recurrence of
psychiatric symptoms may occur. For patients with a recur-
rence of symptoms, the effectiveness of corticosteroid
therapy remains good. Combination of oral prednisone
(1 mg/kg/day) after high-dose corticosteroid can be
considered for patients showing frequent recurrence, fol-
lowed by progressive tapering until the drug is withdrawn
after 6e12 months, depending on clinical evolution and
responsiveness.10,21 In patients with a poor response to
corticosteroids, combination with azathioprine, cyclophos-
phamide, plaquenil, methotrexate, intravenous immuno-
globulin (IVIG), or plasmapheresis has been reported.11,22,23
The second approach is to give thyroxine or an antithy-
roid drug, as it is beneficial to maintain a euthyroid status
for patients with Hashimoto’s encephalopathy. Third,
treatment should be given for other complications: if
a seizure occurs, antiepileptic drugs are considered, and if
cerebral edema is predominant, infusion of mannitol may
also be of benefit to reduce intracranial pressure.
In conclusion, Hashimoto’s encephalopathy is an enceph-
alopathy related to autoimmune thyroid diseases.
Although the laboratory findings are nonspecific except to
prove that the patient has autoimmune thyroid disease,
and the imaging findings are used only to exclude specific
lesions, early diagnosis and treatment is important as the
response to steroid therapy is good. From our experience
with Chinese patients, the dose of corticosteroid pulse
therapy can be lower than that previously suggested in
the literature, with the same dramatic effect.References
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